Diamyd Medical Ab Stock Price To Sales
| DMYD-B Stock | SEK 12.74 0.18 1.39% |
Diamyd Medical AB fundamentals help investors to digest information that contributes to Diamyd Medical's financial success or failures. It also enables traders to predict the movement of Diamyd Stock. The fundamental analysis module provides a way to measure Diamyd Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diamyd Medical stock.
Diamyd |
Diamyd Medical AB Company Price To Sales Analysis
Diamyd Medical's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Diamyd Medical Price To Sales | 2,531 X |
Most of Diamyd Medical's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diamyd Medical AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Diamyd Medical AB has a Price To Sales of 2.53 K times. This is much higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The price to sales for all Sweden stocks is notably lower than that of the firm.
Diamyd Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diamyd Medical's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diamyd Medical could also be used in its relative valuation, which is a method of valuing Diamyd Medical by comparing valuation metrics of similar companies.Diamyd Medical is currently under evaluation in price to sales category among its peers.
Diamyd Fundamentals
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (170.83) % | |||
| Current Valuation | 1.06 B | |||
| Shares Outstanding | 76.93 M | |||
| Shares Owned By Insiders | 35.22 % | |||
| Shares Owned By Institutions | 0.26 % | |||
| Price To Earning | (4.21) X | |||
| Price To Book | 5.67 X | |||
| Price To Sales | 2,531 X | |||
| Revenue | 454 K | |||
| Gross Profit | (3.95 M) | |||
| EBITDA | (98.88 M) | |||
| Net Income | (118.18 M) | |||
| Cash And Equivalents | 119.76 M | |||
| Cash Per Share | 1.02 X | |||
| Current Ratio | 5.83 X | |||
| Book Value Per Share | 2.36 X | |||
| Cash Flow From Operations | (93.22 M) | |||
| Earnings Per Share | (1.45) X | |||
| Number Of Employees | 20 | |||
| Beta | 1.91 | |||
| Market Capitalization | 1.21 B | |||
| Total Asset | 236.52 M | |||
| Retained Earnings | (31 M) | |||
| Working Capital | 28 M | |||
| Current Asset | 33 M | |||
| Current Liabilities | 5 M | |||
| Net Asset | 236.52 M |
About Diamyd Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diamyd Medical AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diamyd Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diamyd Medical AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.